Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iridex (IRIX) Cash & Equivalents (2016 - 2026)

Iridex has reported Cash & Equivalents over the past 17 years, most recently at $6.0 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $6.0 million for Q1 2026, up 152.53% from a year ago — trailing twelve months through Jan 2026 was $6.0 million (up 152.53% YoY), and the annual figure for FY2026 was $6.0 million, up 152.53%.
  • Cash & Equivalents for Q1 2026 was $6.0 million at Iridex, up from $5.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IRIX hit a ceiling of $23.9 million in Q1 2022 and a floor of $2.4 million in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $7.2 million (2025), compared with a mean of $10.0 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 66.06% in 2024 and later skyrocketed 152.53% in 2026.
  • Iridex's Cash & Equivalents stood at $13.9 million in 2022, then plummeted by 49.48% to $7.0 million in 2023, then tumbled by 66.06% to $2.4 million in 2024, then soared by 133.47% to $5.6 million in 2025, then grew by 8.16% to $6.0 million in 2026.
  • The last three reported values for Cash & Equivalents were $6.0 million (Q1 2026), $5.6 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.